Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT05705778
Recruiting Observational

Plasma Biomarker in Amblyopia Patients

NCT05705778 · tracked via the Priya Life Science China tracker
Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Phase
Observational
Started
2022-11-01
Last updated
2023-01-31

Condition(s) studied

Amblyopia

Investigational drug(s) / intervention(s)

standard amblyopia treatment

standard amblyopia treatment: amblyopia treatment following international guidelines and genetic tests.

Study summary

This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.

Eligibility

Sex
ALL
Min age
3 Years
Max age
12 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Diagnosed with amblyopia * 3-12 years of age * Able to tolerate amblyopia treatment * Agree to be involved in this study and agree to have a follow up visit every 3 months. Exclusion Criteria: * Have previous treatment history before * Have pathological ocular anomalies known to cause reduced visual acuity * Have previous psychiatric, visual or neurological disorders * Have eccentric fixation and/or abnormal retinal correspondence * Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves

Primary outcome measure(s)

  • Plasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics — 2 years after including into this clinical trial
    Peripheral blood will be collected prior and after treatment. The plasma will be separated and Tandem Mass Tags will be used for proteomics. We will detect the different expression of plasma protein between successfully treated and untreated amblyopia patients to find biomarkers that predict amblyopia treatment success. Amblyopia treatment success is defined as best corrected visual acuity (BCVA) improvement of 3 or more logMAR lines.

Trial sites (1)

FacilityCityRegionStatus
Zhongshan Ophthalmic Center Guangzhou Guangdong Recruiting

More Zhongshan Ophthalmic Center, Sun Yat-sen University trials in China

A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa Starting soon
Efficacy Evaluation of 5-Fluorouracil as an Adjuvant to Endoscopic Dacryocystorhinostomy in Managing Primary Acquired Nasolacrimal Duct Obstruction With Small Lacrimal Sac: A Randomized Controlled Study Recruiting
Let It TiC in Childhood Provisional Eye Tic Starting soon
Comparison of Two Rotational Alignment Methods for Astigmatism Correction in SMILE Surgery Starting soon
Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control Active, not recruiting

Other trials for the same condition

A Comparative Study of the Efficacy of AR Based Amblyopia Training Therapy and Occlusion Therapy in Older Children and Adults With Amblyopia Starting soon
Clinical Treatment of Transcranial Direct Current Stimulation in Older Adolescents With Amblyopia Recruiting
A Study on the Efficacy and User Experience of Gamified Intervention for Children With Anisometropic Amblyopia Recruiting
A Randomized Controlled Trial of Gabor-Based Perceptual Learning for Adult Amblyopia Recruiting
A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05705778 on ClinicalTrials.gov ↗ ← All trials in China